(Q30785107)

English

Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Effects of different thrombolytic treatment regimen with abciximab and tirofiban on platelet aggregation and platelet-leukocyte interactions: a subgroup analysis from the GUSTO V and FASTER trials (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

1 reference

based on heuristic

inferred from title

platelet aggregation

1 reference

based on heuristic

inferred from title

8

object named as

Christoph Bode

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

author name string

Ulf Bertram

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Martin Moser

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Karlheinz Peter

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Helmut F Kuecherer

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Raffi Bekeredjian

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Andreas Straub

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Thomas K Nordt

7

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Johannes Ruef

9

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

publication date

1 December 2002

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Journal of Thrombosis and Thrombolysis

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

197-203

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Recurrent ischemia after thrombolysis for acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta(3) integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The thrombolytic paradox

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of platelets and plasma on fibrinolysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet aggregation inhibition with glycoprotein IIb--IIIa inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The rationale for thrombolytic therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet function and fibrinolytic agents: two sides of a coin?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid platelet-function assay: an automated and quantitative cartridge-based method

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet glycoprotein IIb/IIIa inhibitors combined with fibrinolytic agents to treat acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A bispecific antifibrin-antiplatelet urokinase conjugate (BAAUC) induces enhanced clot lysis and inhibits platelet aggregation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet activation and inhibition in unstable coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A faster-acting and more potent form of tissue plasminogen activator

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased thrombin levels during thrombolytic therapy in acute myocardial infarction. Relevance for the success of therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Potential non-glycoprotein IIb/IIIa effects of abciximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased neutrophil-platelet adhesion in patients with unstable angina

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of abciximab, ticlopidine, and combined Abciximab/Ticlopidine therapy on platelet and leukocyte function in patients undergoing coronary angioplasty

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlo

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid and sustained coronary artery recanalization with combined bolus injection of recombinant tissue-type plasminogen activator and monoclonal antiplatelet GPIIb/IIIa antibody in a canine preparation

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-GPIIb/IIIa drugs: current strategies and future directions

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of neutrophils with platelet aggregates in unstable angina. Should we alter therapy?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy of abciximab induced platelet blockade using a rapid point of care assay

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coronary angioplasty or intravenous thrombolysis: the dilemma of optimal reperfusion in acute myocardial infarction: A critical review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular bases of the acute coronary syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12913399

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1023/A:1025044625487

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30785107&oldid=2047602284"